Skip to main content
PLOS One logoLink to PLOS One
. 2024 Mar 7;19(3):e0298998. doi: 10.1371/journal.pone.0298998

The relationship between emotional disorders and heart rate variability: A Mendelian randomization study

Xu Luo 1, Rui Wang 1, YunXiang Zhou 1, Wen Xie 1,2,*
Editor: Simone Battaglia3
PMCID: PMC10919610  PMID: 38451975

Abstract

Objective

Previous studies have shown that emotional disorders are negatively associated with heart rate variability (HRV), but the potential causal relationship between genetic susceptibility to emotional disorders and HRV remains unclear. We aimed to perform a Mendelian randomization (MR) study to investigate the potential association between emotional disorders and HRV.

Methods

The data used for this study were obtained from publicly available genome-wide association study datasets. Five models, including the inverse variance weighted model (IVW), the weighted median estimation model (WME), the weighted model-based method (WM), the simple model (SM) and the MR–Egger regression model (MER), were utilized for MR. The leave-one-out sensitivity test, MR pleiotropy residual sum and outlier test (MR-PRESSO) and Cochran’s Q test were used to confirm heterogeneity and pleiotropy.

Results

MR analysis revealed that genetic susceptibility to broad depression was negatively correlated with HRV (pvRSA/HF) (OR = 0.380, 95% CI 0.146–0.992; p = 0.048). However, genetic susceptibility to irritability was positively correlated with HRV (pvRSA/HF, SDNN) (OR = 2.017, 95% CI 1.152–3.534, p = 0.008) (OR = 1.154, 95% CI 1.000–1.331, p = 0.044). Genetic susceptibility to anxiety was positively correlated with HRV (RMSSD) (OR = 2.106, 95% CI 1.032–4.299; p = 0.041). No significant directional pleiotropy or heterogeneity was detected. The accuracy and robustness of these findings were confirmed through a sensitivity analysis.

Conclusions

Our MR study provides genetic support for the causal effects of broad depression, irritable mood, and anxiety on HRV.

1. Introduction

Emotions are continually evoked by stimuli from internal and external environments, and emotions help humans establish connections with each other [1]. The predominance of emotional disorders is mainly caused by difficulty in autonomously regulating or adapting to emotions. Emotional disorders are intrinsic characteristics of personality disorders [2], and they are coexisting symptoms of mental illness. Emotional disorders are characterized by changes in mood or emotions. Furthermore, they are closely associated with many neurological diseases and can impact the emotional, physical, and cognitive levels of patients [3]. The latest report from the Global Burden of Disease Research indicates an increase in the prevalence and burden of emotional disorders over the past two decades [4]. Additionally, emotional disorders have become more common since the COVID-19 epidemic [5], resulting in a high socioeconomic burden. Early recognition of emotional disorders can reduce the incidence and mortality of related diseases [6].

Heart rate variability (HRV) refers to the alteration between two successive heartbeats and is generally measured using time-domain metrics, such as the standard deviation of the normal‐to‐normal interbeat intervals (SDNN), the root mean square of the successive differences in interbeat intervals (RMSSD), and peak‐valley respiratory sinus arrhythmia or high frequency power (pvRSA/HF) [4, 7]. Detecting HRV is not only crucial in evaluating cardiovascular health but also in assessing the parasympathetic and sympathetic components of the autonomic nervous system [8, 9]. Recent studies have demonstrated that HRV analysis also plays an essential role in emotional research and detection [10]. It can be a valuable tool for tracking changes in emotional state and detecting early onset and relapse in individuals with emotional disorders [11]. Previous studies have shown that individuals with emotional disorders are characterized by chronic low heart rate variability compared to healthy individuals [12, 13], but it remains unclear whether a causal relationship exists between emotional disorders and HRV.

Mendelian randomization (MR) analysis uses germline genetic variants as exposure instrumental variables (IVs) to study the causal relationships between the exposure phenotype and the outcome phenotype [14]. Because exposure instrumental variables (IVs) during pregnancy are randomly allocated, they are unlikely to be affected by disease status. Therefore, MR studies can exclude unobserved confounding factors as well as reverse causal relationships and overcome the typical pitfalls present in observational studies [15, 16]. In the present study, we aimed to use MR analysis to investigate the genetic relationships between seven emotional disorders (broad depression, major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bipolar disorder, irritable mood, anxiety, and mania) and HRV.

2. Materials and methods

2.1 Study design and data sources

We conducted MR analysis to assess evidence for causal effects of emotional disorders on HRV. An overview of the research design is presented in Fig 1. To obtain valid results, MRs need to fulfill three key assumptions: (a) genetic variants used in the analysis should be significantly associated with the exposure; (b) genetic variants extracted as instrumental variables for exposure should be independent of confounding factors that are associated with the selected exposure and outcome; and (c) genetic variants should affect the outcome only through exposure and not via other biological pathways [17].

Fig 1. Schematic representation of the Mendelian randomization analysis.

Fig 1

The continuous lines represent the relationships that hold in MR analysis. Broken lines represent associations that violate the assumptions of Mendelian randomization.

We explored publicly available GWAS databases to access eligible datasets on exposure and outcomes. These included databases such as the GWAS catalog, the IEU open GWAS, and the Phe Web. Thus, no further ethical approval was necessary. Since mixed populations may lead to partial estimates, we restricted the genetic background of individuals included in the MR study to those of European ancestry [18].

The data for broad depression originated from the UK Biobank’s GWAS (GWAS ID: ebi-a-GCST005902) [19]. This dataset included 322,580 Europeans (113769 cases and 208811 controls), and 7,624,934 single nucleotide polymorphisms (SNPs) were identified. The data for major depressive disorder (MDD) were retrieved from the NA genome-wide genetic environment analysis (GWAS ID: ebi-a-GCST009979) [20]. The dataset included 92,957 Europeans (29,475 cases and 63,482 controls), and 7,767,934 SNPs were identified. The data on obsessive-compulsive disorder were derived from the PGC genome-wide association analysis (GWAS ID: ieu-a-1189). The dataset comprised 33,925 Europeans (26,888 cases and 7,037 controls), and 8,409,517 SNPs were identified. The data for patients with bipolar disorder were acquired from the GWAS (GWAS ID: ieu-b-41) conducted by the Bipolar Disorder Working Group of the Psychiatric Genomics Consortium [21]. The dataset included 51710 Europeans (20352 cases and 31358 controls), and 13413244 single nucleotide polymorphisms (SNPs) were identified.

The data on irritable mood (GCST006941) were obtained from Nagel M’s genome-wide genotyping array [22]. The dataset included 366,726 Europeans, and 10,847,151 SNPs were identified. The data on anxiety disorders (GCST90267276) were obtained from the Genome-wide genotyping array conducted by Schoeler T [23], which analyzed 282802 Europeans and identified 7296966 SNPs. The data on mania (GCST90044038) were obtained from a genome-wide genotyping array that was carried out by Jiang L [24], which analyzed 146837 Europeans (8,449 cases and 138,388 controls) and identified 11842647 SNPs.

The data presented in the results section were derived from the GWAS public database [25]. Three indices for HRV were used: one dataset (pvRSA/HF) (GWAS ID: ebi-a-GCST004734) included 24088 Europeans and identified 2526821 SNPs; one dataset (RMSSD) (GWAS ID: ebi-a-GCST004733) included 26523 Europeans and identified 2528639 single nucleotide polymorphisms (SNPs); and one dataset (SDNN) (GWAS ID: ebi-a-GCST004734) included 27850 Europeans and identified 2549728 SNPs.

2.2 Selection of instrumental variables

To include eligible instrumental variables, all SNPs in strong linkage disequilibrium (LD) (r2 = 0.001 and kb = 10000) were excluded. The screening threshold was set at p<5 × 10–8, but some exposure data cannot meet the minimum requirements for MR studies with 10 qualified instrumental variables; therefore, a less stringent threshold of p<5 × 10–6 was used [26]. Considering the relatively loose threshold, to reduce potential weak instrumental bias, we calculated the F-statistic. F = R2(N-2)/(1-R2) Within them, R2 indicates the extent to which the instrumental variable explains the factor of exposure. R2=2*(1MAF)*MAF*βSD [27] (MAF denotes the minor allele frequency, β is the effect size for the genetic variant of interest, and SD stands for standard deviation). Given that EAF (effect allele frequency) data could not be obtained for some samples, these data were taken F = Beta2/Se2 (beta (β) and Se data can be directly obtained, where beta (β) is the effect size for the genetic variant of interest and Se denotes the standard error value of beta (β)) [28, 29]. Instrumental variables with F>10 were included in the MR analysis [30]. After intersection of the exposure and outcome data, palindromic SNPs with moderate allele frequencies were removed. Finally, we identified eight SNPs that are broadly associated with depression. Deletion of two palindromic SNPs, namely, rs10947863 and rs7568777, and six SNPs were associated with major depressive disorder (p<5 × 10–6). Four OCD-related SNPs (p<5 × 10–8) were identified after deletion of the palindromic SNP rs909701. After deletion of three palindromic SNPs, namely, rs13231398, rs2314398 and rs5758065, five SNPs associated with bipolar disorder were obtained (p<5 × 10–8). Five palindromic SNPs, namely, rs10228350, rs17151565, rs343949, rs4781534, and rs9630740, were deleted to obtain 16 SNPs associated with irritable mood (p<5 × 10–8). One palindromic SNP, namely, rs4073568, was deleted to obtain 13 SNPs associated with anxiety disorder (p<5 × 10–6) and 5 SNPs associated with mania (p<5 × 10–6). These SNPs serve as appropriate instrumental variables for exploring the potential causal relationship between exposure and outcomes (S1 Table).

2.3 Statistical analysis

The MR-PRESSO software package (version 1.0.0), R software (version 4.3.1), TwoSampleMR (version 0.5.7), gwasglue (version 0.0.0.9000) and gwasvcf (version 0.1.1) packages were used to conduct dual-sample MR analysis.

This study used the inverse variance weighted model (IVM), weighted median estimation model (WME), weighted model-based methods (WM), simple model (SM) and MR Egger model (MER) to estimate the causal relationship between emotional disorders and heart rate variability. The classic IVW is used for the main MR analysis. This approach provides a consistent estimate of the causal effect of exposure on outcomes [31]. The WME is used to combine data from multiple genetic variants into a single causal estimator. Even when up to 50% of the information comes from invalid IVs, this estimator is consistent. It can reduce type 1 errors and estimate more precise causal relationships in the presence of horizontal pleiotropy [32]. Horizontal pleiotropy determines whether a genetic instrument affects an outcome through pathways other than via the exposure of interest [33]. The WM method can provide a robust causal effect estimate for horizontal pleiotropy [34]. The MER method can assess whether genetic variation has a nonzero mean pleiotropy effect on outcomes (directed pleiotropy), and under weaker assumptions, the modification of Egger regression (MR Egger) can be used to detect and correct bias caused by directed pleiotropy [35, 36]. We also used Q-statistics to measure whether there was heterogeneity between instruments. Heterogeneity is caused both by random sampling error and by inherent differences in research design and implementation methods, resulting in changes in observed research estimates [37]. When Q values were significant (P<0.05), we used a multiplicative random effects model based on IVW. In all the other cases, a fixed effects model was used. Further application of MR Egger intercept data and the MR PRESSO method was used to test for horizontal pleiotropy and correct for horizontal pleiotropy by excluding outliers [38]. The stability of MR results is determined by excluding IVs one at a time in a sensitivity test [39].

3. Results

3.1 Emotional disorders and HRV (pvRSA/HF)

The results for the selected emotional disorders and HRV (pvRSA/HF) are shown in Table 1. Scatter plots are shown in S1 Fig. The IVM results showed that genetic susceptibility to broad depression may be associated with HRV (pvRSA/HF) (OR = 0.380, 95% CI = 0.146 0.992; p = 0.048). The WM results showed that genetic susceptibility to irritability may be associated with HRV (pvRSA/HF) (OR = 2.017, 95% CI (1.152 3.534), p = 0.008). There was almost no evidence for a causal relationship between other emotional disorders and HRV (measured by the pvRSA/HF). Moreover, Cochran’s Q test showed no significant heterogeneity between emotional disorders and HRV (pvRSA/HF). In addition, the MR Egger intercept method and the MR PRESO method did not reveal a significant horizontal pleiotropic effect between these SNPs (S2 Table). According to the results of the leave-one-out analysis, after excluding one SNP at a time, the estimated risk of emotional disorders remained consistent with the risk of HRV (pvRSA/HF) (S2 Fig).

Table 1. Mendelian randomization analysis results for emotional disorders and HRV (pvRSA/HF).

Exposure Outcome Inverse variance weighted MR Egger Weighted median Simple mode Weighted mode
OR(95%CI) P OR(95%CI) P OR(95%CI) P OR(95%CI) P OR(95%CI) P
Broad depression 0.380(0.146–0.992) 0.048 0.191 (0.001–25.009) 0.531 0.703(0.183–2.703) 0.608 0.908(0.121–6.779) 0.927 0.940(0.107–8.220) 0.957
Major Depressive Disorder 1.032 (0.864–1.232) 0.731 0.079(0.011–0.540) 0.061 1.047 (0.874–1.254) 0.616 1.169 (0.886–1.543) 0.319 1.104 (0.851–1.433) 0.490
Obsessive Compulsive Disorder Heart rate variability (pvRSA/HF) 0.977(0.898–1.063) 0.589 0.818 (0.632–1.058) 0.265 0.943 (0.872–1.019) 0.139 0.939(0.855–1.030) 0.275 0.936 (0.855–1.026) 0.252
Bipolar Disorder 1.019 (0.888–1.170) 0.789 1.101(0.345–3.515) 0.881 1.013 (0.872–1.178) 0.864 0.980 (0.766–1.252) 0.877 1.007 (0.802–1.265) 0.953
Irritable Mood 1.426(0.892–2.280) 0.138 2.302(0.034–154.164) 0.703 2.017 (1.152–3.534) 0.008 2.241(0.925–5.427) 0.094 2.241 (0.934–5.375) 0.091
Anxiety Disorder 2.519 (0.574–11.051) 0.221 0.537 (0.000–4732.949) 0.896 2.149 (0.264–17.467) 0.474 4.237(0.133–134.804) 0.429 3.735 (0.138–101.432) 0.449
Mania 0.990(0.869–1.127) 0.874 2.238 (0.528–9.488) 0.354 0.980 (0.832–1.155) 0.810 1.086 (0.873–1.352) 0.501 0.933 (0.755–1.152) 0.553

3.2 Emotional disorders and HRV (RMSSD)

The results for the selected emotional disorders and HRV (RMSSD) are shown in Table 2. Scatter plots are shown in S3 Fig. The IVM results showed that genetic susceptibility to anxiety may be associated with HRV (RMSSD) (OR = 2.106, 95% CI (1.032–4.299), p = 0.041). There is no evidence of a causal relationship between other emotional disorders and HRV (RMSSD). Moreover, Cochran’s Q test showed no significant heterogeneity between emotional disorders and HRV (RMSSD). In addition, the MR Egger intercept method and the MR PRESO method did not reveal a significant horizontal pleiotropic effect between these SNPs (S3 Table). According to our leave-one-out analysis, after excluding one SNP at a time, the estimated effect of emotional disorders on the risk of HRV (RMSSD) did not change drastically (S4 Fig).

Table 2. Results of the Mendelian randomization analysis for emotional disorders and HRV (RMSSD).

Exposure Outcome Inverse variance weighted MR Egger Weighted median Simple mode Weighted mode
OR(95%CI) P OR(95%CI) P OR(95%CI) P OR(95%CI) P OR(95%CI) P
Broad depression 1.028(0.617–1.712) 0.917 1.243(0.09–16.764) 0.875 1.344(0.712–2.539) 0.362 1.547(0.537–4.454) 0.446 1.516(0.548–4.193) 0.449
Major Depressive Disorder 1.034(0.974–1.098) 0.274 0.44(0.174–1.114) 0.158 1.013(0.937–1.094) 0.754 1.001(0.892–1.124) 0.986 1.005(0.903–1.119) 0.929
Obsessive Compulsive Disorder Heart rate variability (RMSSD) 0.995(0.967–1.024) 0.738 0.968(0.875–1.072) 0.596 1.002(0.969–1.036) 0.915 1.003(0.958–1.051) 0.900 1.003(0.956–1.053) 0.904
Bipolar Disorder 1.012(0.956–1.07) 0.690 1.06(0.701–1.603) 0.801 1.004(0.942–1.069) 0.909 0.998(0.911–1.094) 0.974 0.999(0.919–1.085) 0.975
Irritable Mood 1.217 (0.988–1.499) 0.065 1.181 (0.181–7.699) 0.864 1.243 (0.952–1.623) 0.110 1.543 (0.899–2.649) 0.136 1.494 (0.929–2.403) 0.119
Anxiety Disorder 2.106 (1.032–4.299) 0.041 14.636 (0.212–1012.318) 0.240 1.633 (0.654–4.077) 0.293 1.684 (0.437–6.480) 0.463 1.684 (0.456–6.222) 0.450
Mania 0.958 (0.899–1.021) 0.186 0.914 (0.450–1.853) 0.818 0.961 (0.895–1.032) 0.277 0.966 (0.877–1.063) 0.515 0.965 (0.885–1.053) 0.469

3.3 Emotional disorders and HRV (SDNN)

The results for the selected emotional disorders and HRV (SDNN) are shown in Table 3. Scatter plots are shown in S5 Fig. According to the IVM results, genetic susceptibility to irritable mood may be associated with HRV (SDNN) (OR = 1.154, 95% CI (1.000–1.331), p = 0.044); however, no evidence suggests such a relationship for other emotional disorders and HRV (SDNN). Additionally, Cochran’s Q test revealed no significant heterogeneity between emotional disorders and HRV (SDNN). Furthermore, the MR Egger intercept method and the MR PRESO method did not reveal a notable horizontal pleiotropic effect between these SNPs (S4 Table). During the leave-one-out analysis, we observed that the estimated risk of emotional disorders remained consistent with the risk of HRV (SDNN) even after excluding one SNP each time (S6 Fig).

Table 3. Results of the Mendelian randomization analysis for emotional disorders and HRV (SDNN).

Exposure Outcome Inverse variance weighted MR Egger Weighted median Simple mode Weighted mode
OR(95%CI) P OR(95%CI) P OR(95%CI) P OR(95%CI) P OR(95%CI) P
Broad depression 1.125(0.802–1.578) 0.496 1.612(0.333–7.819) 0.575 1.058(0.690–1.623) 0.796 0.930(0.452–1.915) 0.849 0.954(0.478–1.901) 0.896
Major Depressive Disorder 1.021(0.961–1.084) 0.506 0.401(0.203–0.793) 0.058 0.971(0.913–1.033) 0.349 0.971(0.871–1.081) 0.613 0.969(0.905–1.037) 0.407
Obsessive Compulsive Disorder Heart rate variability (SDNN) 1.008 (0.988–1.029) 0.432 0.990(0.923–1.061) 0.799 1.015(0.989–1.041) 0.255 1.017(0.982–1.053) 0.417 1.017 (0.983–1.052) 0.413
Bipolar Disorder 0.985 (0.945–1.026) 0.462 1.020 (0.758–1.372) 0.905 0.979(0.931–1.029) 0.404 0.972 (0.905–1.043) 0.473 0.975 (0.913–1.042) 0.502
Irritable Mood 1.154(1.000–1.331) 0.044 1.133(0.320–4.014) 0.849 1.191(0.990–1.432) 0.063 1.438 (0.952–2.173) 0.105 1.413 (0.966–2.068) 0.095
Anxiety Disorder 1.473 (0.879–2.467) 0.142 4.532(0.262–78.415) 0.321 1.178(0.576–2.409) 0.653 1.097 (0.331–3.640) 0.882 0.982 (0.299–3.222) 0.977
Mania 0.982 (0.939–1.028) 0.445 1.014(0.607–1.694) 0.961 0.978(0.927–1.031) 0.411 1.021 (0.946–1.102) 0.616 0.963(0.891–1.040) 0.387

The causal relationships between emotional disorders predicted by genes and the risk of heart rate variability and its subtypes are shown in Fig 2.

Fig 2. Forest plot illustrating the causal relationships between gene-predicted emotional disorders heart rate variability, and the risk of its subtypes.

Fig 2

A: Emotional disorders and HRV (pvRSA/HF). B: Emotional disorders and HRV (RMSSD). C: emotional disorders and HRV (SDNN).

4. Discussion

This study examined the causal relationships between seven emotional disorders, namely, broad depression, severe depressive disorder, obsessive-compulsive disorder, bipolar disorder, irritable mood, anxiety, and manic disorder, and HRV (RMSSD, SDNN, and pvRSA/HF). The study concluded that broad depression is widely associated with a decrease in HRV (pvRSA/HF), irritable mood may be associated with an increase in HRV (SDNN, pvRSA/HF), and anxiety may be associated with an increase in HRV (RMSSD). The study revealed no causal relationships between severe depression, obsessive-compulsive disorder, bipolar disorder, or mania and HRV.

Numerous observational studies and reviews have discussed the link between emotional disorders and heart rate variability. Resting electrocardiograms were recorded for 15 minutes in both the depression patient group and the healthy control group, as documented by Ralf Hartmann and colleagues. The electrocardiogram data were preprocessed to extract heart beat intervals. Following the extraction of HRV parameters using both linear and nonlinear methods, an analysis of differences in these parameters at baseline was conducted. The results indicate that changes in HRV parameter values are positively correlated with changes in the severity of depression symptoms [40]. Celine K et al. [41] included 2250 depression patients and 1982 controls in a random effects meta-analysis. The results showed that depression patients had lower measurements of all HRVs than did healthy controls. This finding strengthens the evidence that a low HRV can potentially increase cardiovascular risk in depressed patients. Norie and colleagues also reported a correlation between depression and HRV [42]. This finding is in line with our findings. Hanife evaluated the function of the autonomic nervous system in patients with obsessive-compulsive disorder and healthy individuals by using HRV parameters. One study revealed that patients with obsessive-compulsive disorder had a significantly greater heart rate and high-frequency power (HF) of HRV than healthy individuals. Moreover, there were no significant differences in other HRV parameters between patients and healthy individuals [43]. Ying and colleagues’ meta-analysis examined 4,897 anxiety patients and 5,559 control individuals and revealed a marked decrease in resting parasympathetic activity (HRV) among AD patients compared to that in the control group [44]. Reut Naim et al. investigated cardiovascular arousal (heart rate (HR) and heart rate variability (HRV)) in youths with irritable mood and reported a correlation between irritable mood and increased heart rate but decreased HRV [45].

Our results are inconsistent with most previous studies in terms of the association between anxiety and irritable mood and HRV. There are several possible reasons for this discrepancy. First, this could be explained by the fact that we employed 2 separate GWASs (one for anxiety or irritability and the other for HRV). The number of individuals with anxiety or irritability was rather low in the HRV GWAS. Another consideration is that the HRV GWAS data were not corrected for heart rate, which is strongly correlated with HRV [46]. Second, the occurrence of emotional disorders is caused by genetic and environmental factors. We investigated the relationship between emotional disorders and HRV from a genetic perspective. A lower HRV may be caused by systemic manifestations of anxiety or irritability, and the HRV is easily influenced by changes in blood pressure and physical activity. These confounding factors cannot be avoided in observational studies. MR studies can reduce confounding bias and suggest significant associations [47]. Finally, the MR study considered lifetime effects rather than short-term effects, which might explain the differences between our findings and previous literature [48]. Therefore, HRV testing is still necessary for patients with anxiety and irritable mood.

The link between affective activity and HRV has largely been attributed to dysregulation of the autonomic nervous system, resulting in a chronic shift toward increased sympathetic activity and decreased parasympathetic activity [49]. A higher HRV indicates enhanced control of the parasympathetic nervous system. Elevated HRV is often considered a marker of psychological resilience and the capacity to react appropriately and flexibly to ever-changing environmental cues. In contrast, a decreased HRV suggests greater control of the sympathetic nervous system, which is often associated with increased impulsivity and greater difficulties in emotional regulation [50]. The neurovisceral integration model posits that shared neural networks support the effective regulation of emotions and HRV [51]. Vagally-mediated heart rate variability (vmHRV) represents a psychophysiological index of inhibitory control [52]. Emotional disorders are related to poor executive control of behavior, as the prefrontal cortex and parasympathetic nervous system are connected through the structure and function of the vagus nerve, and the prefrontal and limbic structures control HRV [52, 53]. Depression and other emotional disorders promote changes in the autonomic nervous system function of vagus nerve contraction and a decrease in prefrontal cortex activity, which are the main reasons for vagus nerve-mediated HRV reduction [54].

Our MR study has several strengths. First, in this MR analysis, the latest GWAS datasets were used to eliminate single-nucleotide polymorphisms associated with exposure and outcomes. Subsequently, we employed five different models to comprehensively investigate the potential relationship between emotional disorders and HRV, thus avoiding traditional confounding factors and inverse causality. Second, our analysis did not reveal any heterogeneity or directional pleiotropy, and sensitivity testing reinforced the stability and accuracy of causal findings. Finally, this study demonstrated a significant suggestive relationship from a genetic perspective, which supports the practical application of HRV detection. It is essential to acknowledge some of the limitations of this research. First, our MR technique employed data aggregated from a GWAS that included a European population. The absence of aggregated data from other regions limits its regional and racial effectiveness. Second, emotional disorders are influenced by subjective factors that are noticeable in research. Additionally, these factors can compromise the validity of the data statistics. Therefore, additional data should be collected and additional magnetic resonance imaging techniques applied to address confounding risk factors to obtain more stable and precise findings. In addition, sex was not differentiated in our study, and potential bias due to sex could not be excluded. Finally, additional research is needed to address the controversial findings of current observational studies.

5. Conclusion

The current two-sample MR study provides evidence for a negative correlation between depression and HRV and a positive correlation of irritable mood and anxiety with HRV. Severe depressive disorder, bipolar disorder, obsessive-compulsive disorder, manic disorder, and HRV were not found to be causal. These outcomes offer novel insights into the genetic aspects of the connection between emotional disorders and heart rate variability. Consequently, to safeguard cardiovascular well-being in people with emotional disorders, it is imperative to perform a clear analysis and monitor HRV.

Supporting information

S1 Table. Specific information on instrumental variables for seven types of emotional disorders.

(DOCX)

pone.0298998.s001.docx (30.1KB, docx)
S2 Table. Heterogeneity and sensitivity analysis results for emotional disorders and HRV (pvRSA/HF).

(DOCX)

pone.0298998.s002.docx (16.1KB, docx)
S3 Table. Heterogeneity and sensitivity analysis results for emotional disorders and HRV (RMSSD).

(DOCX)

pone.0298998.s003.docx (16KB, docx)
S4 Table. Heterogeneity and sensitivity analysis results for emotional disorders and HRV (SDNN).

(DOCX)

pone.0298998.s004.docx (16.1KB, docx)
S1 Fig. Scatter plot of heart rate variability (pvRSA/HF) and emotional disorders.

A. Depression.(broad) B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder E. Irritable Mood F. Anxiety Disorder G. Mania.

(DOCX)

pone.0298998.s005.docx (391.3KB, docx)
S2 Fig. Leave-one-out analysis of heart rate variability (pvRSA/HF) and emotional disorders.

A. Depression (broad) B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder. E. Irritable Mood F. Anxiety Disorder G. Mania.

(DOCX)

pone.0298998.s006.docx (360.9KB, docx)
S3 Fig. Scatter plot of heart rate variability (RMSSD) and emotional disorders.

A. Depression(broad) B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder E. Irritable Mood. F. Anxiety Disorder G. Mania.

(DOCX)

pone.0298998.s007.docx (395KB, docx)
S4 Fig. Leave-one-out analysis of heart rate variability traits (RMSSD) and emotional disorders.

A. Depression (broad). B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder. E. Irritable Mood F. Anxiety Disorder G. Mania.

(DOCX)

pone.0298998.s008.docx (333.1KB, docx)
S5 Fig. Scatter plot of heart rate variability (SDNN) and emotional disorders.

A. Depression(broad) B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder E. Irritable Mood F. Anxiety Disorder G. Mania.

(DOCX)

pone.0298998.s009.docx (398.6KB, docx)
S6 Fig. Leave-one-out analysis of heart rate variability (SDNN) and emotional disorders.

A. Depression (broad) B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder. E. Irritable Mood F. Anxiety Disorder G. Mania.

(DOCX)

pone.0298998.s010.docx (348.8KB, docx)

Data Availability

All relevant datas are within the manuscript and its Supporting Information files.

Funding Statement

This research was financially supported by the Key Project of Sichuan Provincial Department of Science and Technology’funding (NO. 2022YFS0395). State Administration of Traditional Chinese Medicine (NO. 2023MS522.

References

  • 1.Pof-Jordanova N. Emotional Dysregulation is the Core Problem in Psychopathological Manifestations. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2023; 44: 7–16. [DOI] [PubMed] [Google Scholar]
  • 2.Faustino B. Transdiagnostic perspective on psychological inflexibility and emotional dysregulation. Behav Cogn Psychother. 2021; 49: 233–246. doi: 10.1017/S1352465820000600 [DOI] [PubMed] [Google Scholar]
  • 3.Lenger M, Dalkne N, Schwalsberger K, Hagendorfer B, Schonthaler E, Rieger A, et al. Examining the Autonomic Nervous System in the Relationship among Heart Rate Variability, Stress Coping, and Cognitive Ability in Individuals with Psychiatric Disorders. J Clin Med. 2022; 11: 3277. doi: 10.3390/jcm11123277 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Wang Z, Luo Y, Zhang Y, Chen L, Zou Y, Xiao J, et al. Heart rate variability in generalized anxiety disorder, major depressive disorder and panic disorder: A network meta-analysis and systematic review. J Affect Disord. 2023; 330: 259–266. doi: 10.1016/j.jad.2023.03.018 [DOI] [PubMed] [Google Scholar]
  • 5.Aguilera-Martin A, Galvez-Lara M, Cuadrado F, Moreno E, Garcia-Torres F, Vencesla J F,et al. Cost-effectiveness and cost-utility evaluation of individual vs. group transdiagnostic psychological treatment for emotional disorders in primary care (PsicAP-Costs): a multicentre randomized controlled trial protocol. BMC Psychiatry. 2022; 22: 99. doi: 10.1186/s12888-022-03726-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Datta S, Suryadevara U, Cheong J. Mood Disorders. Continuum (Minneap Minn). 2021; 27: 1712–1737. doi: 10.1212/CON.0000000000001051 [DOI] [PubMed] [Google Scholar]
  • 7.Geurts S, Tilly M J, Arshi B, Stricker B H C, Kors J A, Deckers J W, et al. Heart rate variability and atrial fibrillation in the general population: a longitudinal and Mendelian randomization study. Clin Res Cardiol. 2023; 112: 747–758. doi: 10.1007/s00392-022-02072-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Santos-De-Araujo A D, Shida-Marinho R, Pontesp-Silva A. Heart rate variability (HRV): Checklist for observational and experimental studies. Autoimmun Rev. 2022; 21: 103190. doi: 10.1016/j.autrev.2022.103190 [DOI] [PubMed] [Google Scholar]
  • 9.Shanks J, Abukar Y, Lever N A, Pachen M, LeGrice I J, Crossman D J, et al. Reverse re-modelling chronic heart failure by reinstating heart rate variability. Basic Res Cardiol. 2022; 117: 4. doi: 10.1007/s00395-022-00911-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Zhu J, Ji L, Liu C. Heart rate variability monitoring for emotion and disorders of emotion. Physiol Meas. 2019; 40: 064004. doi: 10.1088/1361-6579/ab1887 [DOI] [PubMed] [Google Scholar]
  • 11.Gullett N, Zajkowska Z, Walsh A, Harper R, Mondelli V. Heart rate variability (HRV) as a way to understand associations between the autonomic nervous system (ANS) and affective states: A critical review of the literature. Int J Psychophysiol. 2023; 192: 35–42. doi: 10.1016/j.ijpsycho.2023.08.001 [DOI] [PubMed] [Google Scholar]
  • 12.Visted E, Sorensen L, Osnes B, Svendsen J L, Binder P E, Schanche E. The Association between Self-Reported Difficulties in Emotion Regulation and Heart Rate Variability: The Salient Role of Not Accepting Negative Emotions. Front Psychol. 2017; 8: 328. doi: 10.3389/fpsyg.2017.00328 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Szemenyei E, Kocsel N, Orkenyi A, Kokonyei G. [Emotion regulation and heart rate variability]. Neuropsychopharmacol Hung. 2018; 20: 46–58. [PubMed] [Google Scholar]
  • 14.Smith G D, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol. 2003; 32: 1–22. doi: 10.1093/ije/dyg070 [DOI] [PubMed] [Google Scholar]
  • 15.Burgess S, Davey Smith G, Davies N M, Dudbridge F, Gill D, Glymour M M, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2019; 4: 186. doi: 10.12688/wellcomeopenres.15555.3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wu F, Huang Y, Hu J, Shao Z. Mendelian randomization study of inflammatory bowel disease and bone mineral density. BMC Med. 2020; 18: 312. doi: 10.1186/s12916-020-01778-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Burgess S, Scott R A, Timpson N J, Davey Smith G, Thompson S G, Epic- InterAct Consortium. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015; 30: 543–552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Yin K J, Huang J X, Wang P, Yang X K, Tao S S, Li H M, et al. No Genetic Causal Association Between Periodontitis and Arthritis: A Bidirectional Two-Sample Mendelian Randomization Analysis. Front Immunol. 2022; 13: 808832. doi: 10.3389/fimmu.2022.808832 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Howard D M, Adams M J, Shirali M, Clarke T K, Marioni R E, Davies G, et al. Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. Nat Commun. 2018; 9: 1470. doi: 10.1038/s41467-018-03819-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Coleman J R I, Peyrot W J, Purves K L, Davis K A S, Rayner C, Choi S W, et al. Genome-wide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank. Mol Psychiatry. 2020; 25: 1430–1446. doi: 10.1038/s41380-019-0546-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Stahl E A, Breen G, Forstner A J, McQuillin A, Ripke S, Trubetskoy V et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019; 51: 793–803. doi: 10.1038/s41588-019-0397-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Nagel M, Watanabe K, Stringer S, Posthuma D, van der Sluis S. Item-level analyses reveal genetic heterogeneity in neuroticism. Nat Commun. 2018; 9: 905. doi: 10.1038/s41467-018-03242-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Schoeler T, Speed D, Porcu E, Pirastu N, Pingault J B, Kutalik Z. Participation bias in the UK Biobank distorts genetic associations and downstream analyses. Nat Hum Behav. 2023; 7: 1216–1227. doi: 10.1038/s41562-023-01579-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. Nat Genet. 2021; 53: 1616–1621. doi: 10.1038/s41588-021-00954-4 [DOI] [PubMed] [Google Scholar]
  • 25.Nolte I M, Munoz M L, Tragante V, Amare A T, Jansen R, Vaez A, et al. Genetic loci associated with heart rate variability and their effects on cardiac disease risk. Nat Commun. 2017; 8: 15805. doi: 10.1038/ncomms15805 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Cao Z, Wu Y, Li Q, Li Y, Wu J. A causal relationship between childhood obesity and risk of osteoarthritis: results from a two-sample Mendelian randomization analysis. Ann Med. 2022; 54: 1636–1645. doi: 10.1080/07853890.2022.2085883 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Burgess S, Davies N M, Thompson S G. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016; 40: 597–608. doi: 10.1002/gepi.21998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Southam L, Gilly A, Suveges D, Farmaki A E, Schwartzentruber J, Tachmazidou I, et al. Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits. Nat Commun. 2017; 8: 15606. doi: 10.1038/ncomms15606 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Yun Z, Guo Z, Li X, Shen Y, Nan M, Dong Q, et al. Genetically predicted 486 blood metabolites in relation to risk of colorectal cancer: A Mendelian randomization study. Cancer Med. 2023; 12: 13784–13799. doi: 10.1002/cam4.6022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Burgess S, Thompson S G, Collaboration C C G. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011; 40: 755–764. doi: 10.1093/ije/dyr036 [DOI] [PubMed] [Google Scholar]
  • 31.Yavorska O O, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017; 46: 1734–1739. doi: 10.1093/ije/dyx034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Bowden J, Davey Smith G, Haycock P C, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40: 304–314. doi: 10.1002/gepi.21965 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Millard L A C, Munafo M R, Tilling K, Wootton R E, Davey Smith G. MR-pheWAS with stratification and interaction: Searching for the causal effects of smoking heaviness identified an effect on facial aging. PloS Genet. 2019; 15: e1008353. doi: 10.1371/journal.pgen.1008353 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Hartwig F P, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017; 46: 1985–1998. doi: 10.1093/ije/dyx102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Burgess S, Thompson S G. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017; 32: 377–389. doi: 10.1007/s10654-017-0255-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015; 44: 512–525. doi: 10.1093/ije/dyv080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Langan D. Assessing Heterogeneity in Random-Effects Meta-analysis. Methods Mol Biol. 2022; 2345: 67–89. doi: 10.1007/978-1-0716-1566-9_4 [DOI] [PubMed] [Google Scholar]
  • 38.Verbanck M, Chen C Y, Neale B, Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018; 50: 693–698. doi: 10.1038/s41588-018-0099-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Zheng J, Baird D, Borges M C, Bowden J, Hemani G, Haycock P, et al. Recent Developments in Mendelian Randomization Studies. Curr Epidemiol Rep. 2017; 4: 330–345. doi: 10.1007/s40471-017-0128-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hartmann R, Schmidt F M, Sander C, Hegerl U. Heart Rate Variability as Indicator of Clinical State in Depressio n. Front Psychiatry. 2018; 9: 735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Koch C, Wilhelm M, Salzmann S, Rief W, Euteneuer F. A meta-analysis of heart rate variability in major depression. Psychol Med. 2019; 49: 1948–1957. doi: 10.1017/S0033291719001351 [DOI] [PubMed] [Google Scholar]
  • 42.Koga N, Komatsu Y, Shinozaki R, Ishida I, Shimizu Y, Ishimaru S, et al. Simultaneous monitoring of activity and heart rate variability in depressed patients: A pilot study using a wearable monitor for 3 consecutive days. Neuropsychopharmacol Rep. 2022; 42: 457–467. doi: 10.1002/npr2.12285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Olbrich H, Jahn I, Stengler K, Seifritz E, Colla M. Heart rate variability in obsessive compulsive disorder in comparison to healthy controls and as predictor of treatment response. Clin Neurophysiol. 2022; 138: 123–131. doi: 10.1016/j.clinph.2022.02.029 [DOI] [PubMed] [Google Scholar]
  • 44.Cheng Y C, Su M I, Liu C W, Huang Y C, Huang W L. Heart rate variability in patients with anxiety disorders: A systematic review and meta-analysis. Psychiatry Clin Neurosci. 2022; 76: 292–302. doi: 10.1111/pcn.13356 [DOI] [PubMed] [Google Scholar]
  • 45.Naim R, Goodwin M S, Dombek K, Revzina O, Agorsor C, Lee K, et al. Cardiovascular reactivity as a measure of irritability in a transdiagnostic sample of youth: Preliminary associations. Int J Methods Psychiatr Res. 2021; 30: e1890. doi: 10.1002/mpr.1890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Veeneman R R, Vermeulen J M, Abdellaoui A, Sanderson E, Wootton R E, Tadros R, et al. Exploring the Relationship Between Schizophrenia and Cardiovascular Disease: A Genetic Correlation and Multivariable Mendelian Randomization Study. Schizophr Bull. 2022; 48: 463–473. doi: 10.1093/schbul/sbab132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Morie K P, Crowley M J, Mayes L C, Potenza M N. The process of emotion identification: Considerations for psychiatric disorders. J Psychiatr Res. 2022; 148: 264–74. doi: 10.1016/j.jpsychires.2022.01.053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Gao N, Kong M, Li X, Wei D, Zhu X, Hong Z, et al. Systemic Lupus Erythematosus and Cardiovascular Disease: A Mendelian Randomization Study. Front Immunol. 2022; 13: 908831. doi: 10.3389/fimmu.2022.908831 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Pinter A, Szatmari S JR, Horvath T, Penzlin A I, Barlinn K, Siepmann M, et al. Cardiac dysautonomia in depression–heart rate variability biofeedback as a potential add-on therapy. Neuropsychiatr Dis Treat. 2019; 15: 1287–1310. doi: 10.2147/NDT.S200360 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Heiss S, Vaschillo B, Vaschillo E G, Timko C A, Hormes J M. Heart rate variability as a biobehavioral marker of diverse psychopathologies: A review and argument for an “ideal range”. Neurosci Biobehav Rev. 2021; 121: 144–155. doi: 10.1016/j.neubiorev.2020.12.004 [DOI] [PubMed] [Google Scholar]
  • 51.Tupitsa E, Egbuniwe I, Lloyd W K, Puertollano M, Macdonald B, Joanknecht K, et al. Heart rate variability covaries with amygdala functional connectivity during voluntary emotion regulation. Neuroimage. 2023; 274: 120136 doi: 10.1016/j.neuroimage.2023.120136 [DOI] [PubMed] [Google Scholar]
  • 52.Cattaneo L A, Franquillo A C, Grecucci A, Beccia L, Caretti V, Dadomo H. Is Low Heart Rate Variability Associated with Emotional Dysregulation, Psychopathological Dimensions, and Prefrontal Dysfunctions? An Integrative View. J Pers Med. 2021; 11: 872. doi: 10.3390/jpm11090872 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Beauchaine T P, Thayer J F. Heart rate variability as a transdiagnostic biomarker of psychopathology. Int J Psychophysiol. 2015; 98: 338–350. doi: 10.1016/j.ijpsycho.2015.08.004 [DOI] [PubMed] [Google Scholar]
  • 54.Sgoifo A, Carnevali L, Alfonso Mde L, Amore M. Autonomic dysfunction and heart rate variability in depression. Stress. 2015; 18: 343–352. doi: 10.3109/10253890.2015.1045868 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Simone Battaglia

5 Nov 2023

PONE-D-23-27049The relationship between emotional disorders and heart rate variability:A Mendelian randomizationPLOS ONE

Dear Dr. xie,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 20 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Simone Battaglia

Guest Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Note from Emily Chenette, Editor in Chief of PLOS ONE, and Iain Hrynaszkiewicz, Director of Open Research Solutions at PLOS: Did you know that depositing data in a repository is associated with up to a 25% citation advantage (https://doi.org/10.1371/journal.pone.0230416)? If you’ve not already done so, consider depositing your raw data in a repository to ensure your work is read, appreciated and cited by the largest possible audience. You’ll also earn an Accessible Data icon on your published paper if you deposit your data in any participating repository (https://plos.org/open-science/open-data/#accessible-data).

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. Thank you for stating the following financial disclosure:

“The author(s) received no specific funding for this work.”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

7. Please ensure that you refer to Figure 1 in your text as, if accepted, production will need this reference to link the reader to the figure.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the present study, entitled “The relationship between emotional disorders and heart rate variability: A Mendelian randomization”, authors utilize Mendelian randomization to study the development of heart rate variability (HRV) irregularities in people with various psychiatric disorders. To do so, they analysed public genome-wide association study datasets for emotional disorders and heart rate variability and by means of Mendelian randomization highlighted a causal relationship between depression, anxiety, and irritable mood on HRV irregularities.

Despite the interesting results found by the authors, there are some major limitations, affecting the clarity of the manuscript that the authors should address, as well as other relatively minor comments to improve the paper. In general, I think the idea of the study is interesting and might be of interest to the readers of PLOS One, but some adjustments are required before publication.

Major comments

- Throughout the manuscript the words used to define psychiatric disorders are incoherent between them. As an example, in the abstract depression is presented as “Generalized depression”, “Major depressive disorder”, and “Widespread depression”. These seem arbitrary definitions and I would suggest sticking to a single definition that is agreed upon by the scientific literature, such as “Major depressive disorder” if considering the example above.

- At the current state, the introduction prefaces how the study is carried out and the theoretical background, but it lacks a clear and direct statement about the scope of this work, which is only briefly mentioned in the abstract.

- In many circumstances the sentences used need a citation to support the content with evidence from the literature. This is evident especially, but not only, in the methods section. As an example, at page 3, line 71 the text reads: “Since mixed populations may lead to partial estimates, we restricted the genetic background of individuals included in the MR study to those of European ancestry”. I believe that such a sentence needs to be backed up by literature that supports this decision.

- Page 5, line 103 reads: “As EAF data could not be obtained for some samples, they were taken = 2/2 (Beta and Se data can be directly obtained).”. What does EAF stand for? It has not been used in any other part of the manuscript, nor has it been defined. What is “Se”? Again, it is not mentioned anywhere else. Moreover, the rationale behind this decision is not explained, nor it is supported by the bibliography (a problem mentioned in the comment above). I would suggest to carefully go over both the methods and results section of the manuscript to ensure that:

o All acronyms are appropriately defined and explained,

o Sentences that require a citation are given an appropriate one.

- Given the interdisciplinary readership of PLOS One, which comes from different academic backgrounds, a brief primer on Mendelian randomization in the introduction is highly recommended. On many occasions throughout the text the authors use words such as heterogeneity or horizontal pleiotropy which have a specific meaning in the context of MR but leave a non-expert reader wondering what they mean, as no explanation is given.

- It must be made clear why the author’s results provide causality. Suggested reads:

o Davey Smith, G., & Ebrahim, S. (2003). ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? International journal of epidemiology, 32(1), 1-22.

o Tian, D., Zhang, L., Zhuang, Z., Huang, T., & Fan, D. (2021). A two-sample Mendelian randomization analysis of heart rate variability and cerebral small vessel disease. Journal of clinical hypertension (Greenwich, Conn.), 23(8), 1608–1614. https://doi.org/10.1111/jch.14316

- Authors state throughout the manuscript about the causal relationship between mental health and HRV. But in these terms, it does not make sense. What is different in HRV about these patients as opposed to the healthy population? Based on the literature, I think it would be more appropriate to talk about a link between psychiatric disorders and a reduced HRV, hence a more regular heartbeat (see Koch et al., 2019 https://doi.org/10.1017/S0033291719001351; Chalmers et al., 2014 https://doi.org/10.3389/fpsyt.2014.00080). This needs to be stated clearly.

- Page 11, line 233: After stating multiple times that the results provide causality, the authors now state that their study failed to establish a causal relationship. Is this a typo? Moreover, immediately after it is suggested that additional (to what, since there is no imaging data in this study?) magnetic resonance imaging techniques are needed to address confounding factors, but I do not believe this is in any way relevant with the topic at hand. I suggest the authors carefully revise this section of the manuscript.

- Page 12, line 241: The last sentence needs to be rephrased. “to safeguard cardiovascular well-being,” seems to refer to everyone, but in this case it would be better to specify the “cardiovascular well-being of people with emotional disorders”. Moreover, the authors suggest a clear analysis, but not what needs to undergo such analysis. Notwithstanding, I would not say that this is imperative, but it may be a suggestion for future research and clinical practice. Finally, since the correlation between emotional disorders and aberrant heart rate behavior is a well-established phenomenon (Battaglia et al., 2023a https://10.1016/j.neubiorev.2023.105163; Battaglia et al., 2023b https://10.1111/acps.13602), I would put more emphasis on the idea of causality that emerges from the results and why it is relevant.

Minor comments

- I believe the abstract goes too much into detail in regard to both the methodology and the results section. I suggest removing the last sentence in the “Methods” subsection, as well as removing the result of the analyses in parentheses and simply describing the findings in more direct and concise sentences.

- The manuscript would benefit from a native speaker proofreading service, as there are some grammatical errors throughout the text.

- Page 9, line 178 and 180: Change SNDD to SDNN

Reviewer #2: Thank you for the opportunity to review this interesting manuscript. The manuscript examines the causative associations between emotional disorders and heart rate variability (HRV) measures using Mendelian randomization. Five models were included for the MR analysis. The models show causal relationships between widespread depression, angry emotions and one HRV trait (PVRSA/HF), and between the HRV trait (SDNN) and angry emotions. Finally, Anxiety and HRV trait (RMSSD) have a causal relationship. The manuscript is well written, methodology and sample size are appropriate. I have few comments.

Introduction

Pag 4. Previous studies (if any) linking specific HRV measures and emotional disorders should be reported to clarify present study predictions and hypotheses.

Methods

Although the methods and the statistical strategy are clearly defined, I suggest to include a schematic figure that synthetize the main statistical procedures within the MR (IV, exposure, model application, outcomes etc) (Tian D, Zhang L, Zhuang Z, Huang T, Fan D. A two-sample Mendelian randomization analysis of heart rate variability and cerebral small vessel disease. J Clin Hypertens (Greenwich). 2021 Aug;23(8):1608-1614. doi: 10.1111/jch.14316)

The selection of instrumental variables is based on different analytic steps and parameters, I suggest to include appropriate references that justify the used parameters.

Discussion

Results show that different emotional diseases are linked to specific HRV indices. May the authors discuss the possible functional mechanisms that can explain these differential effects? (S. Battaglia, C. Nazzi, J.F. Thayer, Fear-induced bradycardia in mental disorders: Foundations, current advances, future perspectives, Neuroscience & Biobehavioral Reviews, Volume 149,2023,105163,ISSN 0149-7634 https://doi.org/10.1016/j.neubiorev.2023.105163; Jung W, Jang KI, Lee SH. Heart and Brain Interaction of Psychiatric Illness: A Review Focused on Heart Rate Variability, Cognitive Function, and Quantitative Electroencephalography. Clin Psychopharmacol Neurosci. 2019 Nov 20;17(4):459-474. doi: 10.9758/cpn.2019.17.4.459)

Minor:

ABSTRACT: widespread depression and HRVT (PVRSA/HF). The existence 25 of a causal relationship

26 between HRVT (pvRSA/HF). Use the same format for pvRSA/HF

Keywords are a simple repetition of the title, I suggest to use different MeSH words

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Mar 7;19(3):e0298998. doi: 10.1371/journal.pone.0298998.r002

Author response to Decision Letter 0


19 Dec 2023

Reviewer 1

Thank you very much for your valuable comments to improve the quality of our manuscript. All questions have been answered in itemized descriptions as shown below.

Major comments

1.Throughout the manuscript the words used to define psychiatric disorders are incoherent between them. As an example, in the abstract depression is presented as “Generalized depression”, “Major depressive disorder”, and “Widespread depression”. These seem arbitrary definitions and I would suggest sticking to a single definition that is agreed upon by the scientific literature, such as “Major depressive disorder” if considering the example above.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, Depression (broad) was revised to broad depression in the Revised Manuscript with Track Changes and Manuscript. (References[19]).

2.At the current state, the introduction prefaces how the study is carried out and the theoretical background, but it lacks a clear and direct statement about the scope of this work, which is only briefly mentioned in the abstract.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes (Page: 4, line: 73-76) and Manuscript(Page: 3, line: 56-58).

3.In many circumstances the sentences used need a citation to support the content with evidence from the literature. This is evident especially, but not only, in the methods section. As an example, at Page: 3, line 71 the text reads: “Since mixed populations may lead to partial estimates, we restricted the genetic background of individuals included in the MR study to those of European ancestry”. I believe that such a sentence needs to be backed up by literature that supports this decision.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes and Manuscript (References[18]).

4.Page: 5, line 103 reads: “As EAF data could not be obtained for some samples, they were taken = 2/2 (Beta and Se data can be directly obtained).”. What does EAF stand for? It has not been used in any other part of the manuscript, nor has it been defined. What is “Se”? Again, it is not mentioned anywhere else. Moreover, the rationale behind this decision is not explained, nor it is supported by the bibliography (a problem mentioned in the comment above). I would suggest to carefully go over both the methods and results section of the manuscript to ensure that:

o All acronyms are appropriately defined and explained,

o Sentences that require a citation are given an appropriate one.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes (Page:6, lines:123-127)and Manuscript (Page:5, lines:100-104).

5.Given the interdisciplinary readership of PLOS One, which comes from different academic backgrounds, a brief primer on Mendelian randomization in the introduction is highly recommended. On many occasions throughout the text the authors use words such as heterogeneity or horizontal pleiotropy which have a specific meaning in the context of MR but leave a non-expert reader wondering what they mean, as no explanation is given.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes (Page:7, lines:149-151,lines:155-157) and Manuscript (Page:6, lines:125-127, lines:131-133).

6.It must be made clear why the author’s results provide causality. Suggested reads:

o Davey Smith, G., & Ebrahim, S. (2003). ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? International journal of epidemiology, 32(1), 1-22.

o Tian, D., Zhang, L., Zhuang, Z., Huang, T., & Fan, D. (2021). A two-sample Mendelian randomization analysis of heart rate variability and cerebral small vessel disease. Journal of clinical hypertension (Greenwich, Conn.), 23(8), 1608–1614. https://doi.org/10.1111/jch.14316

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes (Page:8, lines:166-169; Page:9, lines:180-182;Page:10, lines:191-193;Page:13-14, lines:247-268) and Manuscript (Page:7, lines:141-144; Page:8 lines:154-155; Page:9 lines:165-166; Page:12, lines:217-230).

7.Authors state throughout the manuscript about the causal relationship between mental health and HRV. But in these terms, it does not make sense. What is different in HRV about these patients as opposed to the healthy population? Based on the literature, I think it would be more appropriate to talk about a link between psychiatric disorders and a reduced HRV, hence a more regular heartbeat

(see Koch et al., 2019 https://doi.org/10.1017/S0033291719001351;

Chalmers etal.2014 https://doi.org/10.3389/fpsyt.2014.00080). This needs to be stated clearly.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes (Page:1, lines:10; Page: 3, lines:62-64; Page:11, lines:207-210) and Manuscript (Page:1, lines:8-9; Page:3 lines:48-50; Page:10 lines:179-182). 2. MR analysis showed that genetic susceptibility to broad depression was negatively correlated with HRV. However,anxiety genetic susceptibility to irritability emotions was positively correlated with HRV. Therefore, this study systematically investigated the potential link between genetic determined emotional disorders and HRV. The possible reasons for the discrepancy between the results of this study and clinical research have been added in the Revised Manuscript with Track Changes ( Page:12-13, lines:232-246) and Manuscript (Page:11-12, lines:204-216).

8.Page: 11, line 233: After stating multiple times that the results provide causality, the authors now state that their study failed to establish a causal relationship. Is this a typo? Moreover, immediately after it is suggested that additional (to what, since there is no imaging data in this study?) magnetic resonance imaging techniques are needed to address confounding factors, but I do not believe this is in any way relevant with the topic at hand. I suggest the authors carefully revise this section of the manuscript. Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes (Page:15, lines:287-289).

9.Page: 12, line 241: The last sentence needs to be rephrased. “to safeguard cardiovascular well-being,” seems to refer to everyone, but in this case it would be better to specify the “cardiovascular well-being of people with emotional disorders”. Moreover, the authors suggest a clear analysis, but not what needs to undergo such analysis. Notwithstanding, I would not say that this is imperative, but it may be a suggestion for future research and clinical practice. Finally, since the correlation between emotional disorders and aberrant heart rate behavior is a well-established phenomenon (Battaglia et al., 2023a https://10.1016/j.neubiorev.2023.105163; Battaglia et al., 2023b https://10.1111/acps.13602), I would put more emphasis on the idea of causality that emerges from the results and why it is relevant.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes (Page:15 lines:296-298, lines:301-303)and Manuscript (Page:13, lines:247-252).

Minor comments

1.I believe the abstract goes too much into detail in regard to both the methodology and the results section. I suggest removing the last sentence in the “Methods” subsection, as well as removing the result of the analyses in parentheses and simply describing the findings in more direct and concise sentences.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes(Page:1-2,line:16-35)and Manuscript (Page:1-2, lines:12-24).

2.The manuscript would benefit from a native speaker proofreading service, as there are some grammatical errors throughout the text.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes and Manuscript.

3. Page: 9, line 178 and 180: Change SNDD to SDNN

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes(Page:11,line:206) and Manuscript (Page:10, lines:179).

Reviewer 2: Thank you for the opportunity to review this interesting manuscript. The manuscript examines the causative associations between emotional disorders and heart rate variability (HRV) measures using Mendelian randomization. Five models were included for the MR analysis. The models show causal relationships between widespread depression, angry emotions and one HRV trait (PVRSA/HF), and between the HRV trait (SDNN) and angry emotions. Finally, Anxiety and HRV trait (RMSSD) have a causal relationship. The manuscript is well written, methodology and sample size are appropriate. I have few comments.

Response:Thank you very much for your valuable comments to improve the quality of our manuscript. All questions have been answered in itemized descriptions as shown below.

1. Introduction. Pag 4. Previous studies (if any) linking specific HRV measures and emotional disorders should be reported to clarify present study predictions and hypotheses.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes (Page:3,line:62-64) and Manuscript (Page:3, lines:48-50).

2.Methods. Although the methods and the statistical strategy are clearly defined, I suggest to include a schematic figure that synthetize the main statistical procedures within the MR (IV, exposure, model application, outcomes etc) (Tian D, Zhang L, Zhuang Z, Huang T, Fan D. A two-sample Mendelian randomization analysis of heart rate variability and cerebral small vessel disease. J Clin Hypertens (Greenwich). 2021 Aug;23(8):1608-1614. doi: 10.1111/jch.14316)

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes and Manuscript( Figure 1).

3.The selection of instrumental variables is based on different analytic steps and parameters, I suggest to include appropriate references that justify the used parameters.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes and Manuscript (References:26-30)

4.Discussion.Results show that different emotional diseases are linked to specific HRV indices. May the authors discuss the possible functional mechanisms that can explain these differential effects? (S. Battaglia, C. Nazzi, J.F. Thayer, Fear-induced bradycardia in mental disorders: Foundations, current advances, future perspectives, Neuroscience & Biobehavioral Reviews, Volume 149,2023,105163,ISSN 0149-7634 https://doi.org/10.1016/j.neubiorev.2023.105163; Jung W, Jang KI, Lee SH. Heart and Brain Interaction of Psychiatric Illness: A Review Focused on Heart Rate Variability, Cognitive Function, and Quantitative Electroencephalography. Clin Psychopharmacol Neurosci. 2019 Nov 20;17(4):459-474. Doi: 10.9758/cpn.2019.17.4.459)

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes. (Page:12-14,line:232-268)and Manuscript (Page:11-12, lines:204-230).

Minor:

1.ABSTRACT: widespread depression and HRVT (PVRSA/HF). The existence 25 of a causal relationship

26 between HRVT (pvRSA/HF). Use the same format for pvRSA/HF

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes and Manuscript.

2.Keywords are a simple repetition of the title, I suggest to use different MeSH words

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes (Page:2,line:41-42)and Manuscript (Page:2, lines:27-28).

Attachment

Submitted filename: Response to Reviewers.docx

pone.0298998.s011.docx (22.7KB, docx)

Decision Letter 1

Simone Battaglia

18 Jan 2024

PONE-D-23-27049R1The relationship between emotional disorders and heart rate variability:A Mendelian randomizationPLOS ONE

Dear Dr. xie,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 03 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Simone Battaglia

Guest Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All comments have been addressed, but there are still many typos, grammatical errors and punctuation errors. Despite the authors stated that the manuscript already underwent proofreading, I strongly suggest having it edited once more, referring to a professional native speaker proofreader. The inaccuracies present within the manuscript as of now negatively impact on its quality, and need to be addressed before publication.

Reviewer #2: I thank the authors for their response. I believe they addressed all of my comments satisfactorily. I have no additional comments to add.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Mar 7;19(3):e0298998. doi: 10.1371/journal.pone.0298998.r004

Author response to Decision Letter 1


25 Jan 2024

Reviewer 1

Thank you very much again for your valuable comments to improve the quality of our manuscript. All questions have been answered in itemized descriptions as shown below.

Major comments

1.All comments have been addressed, but there are still many typos, grammatical errors and punctuation errors. Despite the authors stated that the manuscript already underwent proofreading, I strongly suggest having it edited once more, referring to a professional native speaker proofreader. The inaccuracies present within the manuscript as of now negatively impact on its quality, and need to be addressed before publication.

Response:

Many thanks for your valuable comments for improving the quality of our manuscript. Accordingly, the correction has been made in the Revised Manuscript with Track Changes and Manuscript.

Reviewer 2: I thank the authors for their response. I believe they addressed all of my comments satisfactorily. I have no additional comments to add.

Thank you very much again for your valuable comments to improve the quality of our manuscript.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0298998.s012.docx (16KB, docx)

Decision Letter 2

Simone Battaglia

5 Feb 2024

The relationship between emotional disorders and heart rate variability: A Mendelian ​randomization study

PONE-D-23-27049R2

Dear Dr. Xu Luo,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Simone Battaglia

Guest Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Acceptance letter

Simone Battaglia

26 Feb 2024

PONE-D-23-27049R2

PLOS ONE

Dear Dr. Xie,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Simone Battaglia

Guest Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Specific information on instrumental variables for seven types of emotional disorders.

    (DOCX)

    pone.0298998.s001.docx (30.1KB, docx)
    S2 Table. Heterogeneity and sensitivity analysis results for emotional disorders and HRV (pvRSA/HF).

    (DOCX)

    pone.0298998.s002.docx (16.1KB, docx)
    S3 Table. Heterogeneity and sensitivity analysis results for emotional disorders and HRV (RMSSD).

    (DOCX)

    pone.0298998.s003.docx (16KB, docx)
    S4 Table. Heterogeneity and sensitivity analysis results for emotional disorders and HRV (SDNN).

    (DOCX)

    pone.0298998.s004.docx (16.1KB, docx)
    S1 Fig. Scatter plot of heart rate variability (pvRSA/HF) and emotional disorders.

    A. Depression.(broad) B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder E. Irritable Mood F. Anxiety Disorder G. Mania.

    (DOCX)

    pone.0298998.s005.docx (391.3KB, docx)
    S2 Fig. Leave-one-out analysis of heart rate variability (pvRSA/HF) and emotional disorders.

    A. Depression (broad) B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder. E. Irritable Mood F. Anxiety Disorder G. Mania.

    (DOCX)

    pone.0298998.s006.docx (360.9KB, docx)
    S3 Fig. Scatter plot of heart rate variability (RMSSD) and emotional disorders.

    A. Depression(broad) B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder E. Irritable Mood. F. Anxiety Disorder G. Mania.

    (DOCX)

    pone.0298998.s007.docx (395KB, docx)
    S4 Fig. Leave-one-out analysis of heart rate variability traits (RMSSD) and emotional disorders.

    A. Depression (broad). B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder. E. Irritable Mood F. Anxiety Disorder G. Mania.

    (DOCX)

    pone.0298998.s008.docx (333.1KB, docx)
    S5 Fig. Scatter plot of heart rate variability (SDNN) and emotional disorders.

    A. Depression(broad) B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder E. Irritable Mood F. Anxiety Disorder G. Mania.

    (DOCX)

    pone.0298998.s009.docx (398.6KB, docx)
    S6 Fig. Leave-one-out analysis of heart rate variability (SDNN) and emotional disorders.

    A. Depression (broad) B. Major Depressive Disorder C. Obsessive Compulsive Disorder D. Bipolar Disorder. E. Irritable Mood F. Anxiety Disorder G. Mania.

    (DOCX)

    pone.0298998.s010.docx (348.8KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0298998.s011.docx (22.7KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0298998.s012.docx (16KB, docx)

    Data Availability Statement

    All relevant datas are within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES